Evaluation of severe neutropenia and diarrhea in Asian cancer patients receiving UGT1A1 genotype-guided irinotecan dosing.

被引：0
|
作者：
Sutiman, Natalia
Ramasamy, Saminathan
Ng, Chau Hsien Matthew
Choo, SuPin
Wenrui, Rachel Lim
Ling, Clarinda Chua Wei
Kuang, John Chia Whay
Tan, Iain B.
Chowbay, Balram
机构：
[1] SingHlth Clin Pharmacol, Singapore, Singapore
[2] Natl Canc Ctr, Div Med Sci, Clin Pharmacol Lab, Singapore, Singapore
[3] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e13572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13572
引用
收藏
页数：1
相关论文
共 50 条
  • [21] UGT1A1*6/*28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients
    Gao, Jing
    Zhou, Jun
    Li, Yanyan
    Lu, Ming
    Jia, Ru
    Shen, Lin
    MEDICAL ONCOLOGY, 2013, 30 (03)
  • [22] UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients
    Masahide Onoue
    Tomohiro Terada
    Masahiko Kobayashi
    Toshiya Katsura
    Shigemi Matsumoto
    Kazuhiro Yanagihara
    Takafumi Nishimura
    Masashi Kanai
    Satoshi Teramukai
    Akira Shimizu
    Masanori Fukushima
    Ken-ichi Inui
    International Journal of Clinical Oncology, 2009, 14 : 136 - 142
  • [23] UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients
    Onoue, Masahide
    Terada, Tomohiro
    Kobayashi, Masahiko
    Katsura, Toshiya
    Matsumoto, Shigemi
    Yanagihara, Kazuhiro
    Nishimura, Takafumi
    Kanai, Masashi
    Teramukai, Satoshi
    Shimizu, Akira
    Fukushima, Masanori
    Inui, Ken-ichi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (02) : 136 - 142
  • [24] Perioperative (P) UGT1A1 genotype guided irinotecan (iri) dosing 'gFOLFIRINOX' for gastroesophageal adenocarcinoma (GEA).
    Catenacci, Daniel V. T.
    Chase, Leah
    Lomnicki, Samantha
    Karrison, Theodore
    Marsh, Robert de Wilton
    Rampurwala, Murtuza M.
    Narula, Sunil
    Alpert, Lindsay
    Setia, Namrata
    Xiao, Shu-Yuan
    Hart, John
    Siddiqui, Uzma
    Liao, Chih-Yi
    Polite, Blase N.
    Kindler, Hedy L.
    Turaga, Kiran
    Prachand, Vivek N.
    Roggin, Kevin K.
    Ferguson, Mark K.
    Posner, Mitchell C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters
    Hoskins, Janelle M.
    Goldberg, Richard M.
    Qu, Pingping
    Ibrahim, Joseph G.
    McLeod, Howard L.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (17) : 1290 - 1295
  • [26] Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer
    Innocenti, Federico
    Schilsky, Richard L.
    Ramirez, Jacqueline
    Janisch, Linda
    Undevia, Samir
    House, Larry K.
    Das, Soma
    Wu, Kehua
    Turcich, Michelle
    Marsh, Robert
    Karrison, Theodore
    Maitland, Michael L.
    Salgia, Ravi
    Ratain, Mark J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (22) : 2328 - 2334
  • [27] Evaluation of the role of UGT1A1 genotype testing in colorectal cancer patients administered irinotecan and the occurence of grade 3 and 4 neutropenia.
    Patel, Sushma M.
    Chan, Jim
    Hui, Rita L.
    Spence, Michele M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [28] A genotype-directed study to optimize dosing of irinotecan according to the UGT1A1 genotype.
    Innocenti, Federico
    Salgia, Ravi
    Ramirez, Jacqueline
    Janisch, Linda A.
    Undevia, Samir D.
    House, Larry
    Das, Soma
    Wu, Kehua
    Turcich, Michelle
    Marsh, Robert de Wilton
    Karrison, Theodore
    Maitland, Michael L.
    Schilsky, Richard L.
    Ratain, Mark J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] UGT1A1 promoter genotype correlates with pharmacokinetics but not toxicity in patients receiving protracted irinotecan (IRN).
    Stewart, C. F.
    Panetta, J. C.
    O'Shaughnessy, M.
    Throm, S.
    Liu, T.
    Billups, C.
    Gajjar, A.
    Furman, W. L.
    McGregor, L. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 140S - 140S
  • [30] A homozygous UGT1A1*28 genotype appears to predict grade 3−4 treatment-induced neutropenia in patients receiving irinotecan,
    Reactions Weekly, 2010, 1292 (1) : 3 - 3
12345